
Eagle Pharmaceuticals (EGRX) announced the divestiture of the marketing authorization for Barhemsys in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment of Postoperative Nausea and
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| EGRX | Eagle Pharmaceuticals | 0.90 | -0.40 | -30.77% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.90 | -30.77% |

Eagle Pharmaceuticals (EGRX) announced the divestiture of the marketing authorization for Barhemsys in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment of Postoperative Nausea and

New option listings for April 21st include EnzymeBioSystems (ENZB) and Gen Digital Inc. (GENVR). Option delistings effective April 21st include Moneylion (ML), Lilium NV (LILMF), Kaixin Auto (KXIN), Hyzon Motors

Eagle Pharmaceuticals (EGRX) announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital, dated March 31

Eagle Pharmaceuticals ( ($EGRX) ) just unveiled an update. Eagle Pharmaceuticals has appointed Christopher Krawtschuk as its new Chief Financial Officer, effective November 11, 2024. With a rich background in

Eagle Pharmaceuticals (EGRX) announced the appointment of Christopher Krawtschuk as CFO of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk’s appointment, Steven Ratoff stepped down from his

The latest announcement is out from Eagle Pharmaceuticals ( ($EGRX) ). Eagle Pharmaceuticals has implemented a limited duration stockholder rights plan to address the ongoing volatility in its stock price,

Eagle Pharmaceuticals (EGRX) announced that its Board of Directors has adopted a limited duration stockholder rights agreement, effective immediately. The Company continues to experience a significant dislocation in the trading

Eagle Pharmaceuticals ( ($EGRX) ) just unveiled an announcement. The Company is actively exploring a variety of financial options to enhance its liquidity and solidify its capital structure, though the

In a regulatory agreement, Eagle Pharmaceuticals said: “Under the terms of the Third Amended and Restated Credit Agreement, dated November 1, 2022, among the Company, the lenders party thereto and

In a regulatory filing, Eagle Pharmaceuticals said that on October 1, the company notified the hearings panel of The Nasdaq Stock Market LLC that the company did not anticipate filing
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| May 10, 2027TBA | $11.72M | ― | ― | -0.02 | 0.08 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.